Skip to main content

Table 10 Occurrence of adverse events suggestive of heart failure in 24 placebo-controlled trials of linagliptin

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

  Linagliptin Placebo
  (n = 5488) (n = 3290)
Cardiac failure (narrow SMQ)*, n (%) 26 (0.5) 8 (0.2)
Acute pulmonary edema 1 (0.0) 1 (0.0)
Cardiac failure 6 (0.1) 2 (0.1)
Cardiac failure, acute 2 (0.0) 0 (0.0)
Cardiac failure, chronic 1 (0.0) 0 (0.0)
Cardiac failure, congestive 7 (0.1) 5 (0.2)
Cardiogenic shock 2 (0.0) 0 (0.0)
Cardiopulmonary failure 1 (0.0) 0 (0.0)
Left ventricular failure 6 (0.1) 0 (0.0)
Pulmonary edema 1 (0.0) 2 (0.1)
Right ventricular failure 1 (0.0) 0 (0.0)
  1. MedDRA, Medical Dictionary for Regulatory Activities; SMQ, standardized MedDRA queries.
  2. Data are based on MedDRA version 16.0.
  3. *Heart failure data are a total of the narrow SMQ listed. Individual patients may have had >1 event.